Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. With rapid advancements in consumer access to diagnostic tests, the in vitro diagnostic (IVD) industry is bridging gaps in care to deliver a seamless and convenient consumer experience.
• Superior sensor performance, short turnaround times, low system complexity, compact designs, seamless data transmission, and minimized user intervention are essential features of scalable PCR-based PoC platforms.
• As multiplexing continues to prove its benefits to patients and public health, it induces an important shift in diagnostic and surveillance efforts (that is, the shift from high-priority samples to comprehensive testing of large samples).
• With improvements in throughput capabilities, sample-to-answer PoC platforms will inspire the development of the multimodal IVD testing ecosystem.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
